Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
暂无分享,去创建一个
R. Herbst | E. Rasmussen | R. Kurzrock | J. Evelhoch | N. Le | D. Hong | J. Oliner | L. Rosen | L. Chap | Yu‐Nien Sun | E. Jackson | Y. Hwang | J. Silverman | D. Zhong
[1] S. Paggi,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[2] K. Flaherty,et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma , 2008, Cancer biology & therapy.
[3] J. Drevs,et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[5] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[6] R. Herbst. Therapeutic options to target angiogenesis in human malignancies , 2006, Expert opinion on emerging drugs.
[7] J. Desai,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[8] Kevin Camphausen,et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Benjamin M Yeh,et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Alitalo,et al. Molecular lymphangiogenesis: new players. , 2005, Trends in cell biology.
[11] G. Yancopoulos,et al. Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period , 2005, Development.
[12] Thomas Hartmann,et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.
[13] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[14] P. Campochiaro,et al. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood–retinal barrier , 2004, Gene Therapy.
[15] P. Sismondi,et al. Angiopoietin‐2 expression in breast cancer correlates with lymph node invasion and short survival , 2003, International journal of cancer.
[16] M. Teh,et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. , 2002, Experimental cell research.
[17] S. Harper,et al. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. , 2002, Journal of the American Society of Nephrology : JASN.
[18] S. Kitano,et al. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. , 2001, Cancer research.
[19] L. Ellis,et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. , 2001, Cancer research.
[20] R. Kalb,et al. Angiopoietin-1 Inhibits Endothelial Cell Apoptosis via the Akt/Survivin Pathway* , 2000, The Journal of Biological Chemistry.
[21] L. Mariani,et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. , 1999, The American journal of pathology.
[22] J L Evelhoch,et al. Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.
[23] G. Yancopoulos,et al. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. , 1999, Genes & development.
[24] N. Copeland,et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[25] H. Gröne,et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. , 1998, Journal of the American Society of Nephrology : JASN.
[26] K. Alitalo,et al. Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.
[27] K. Plate,et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. , 1995, The American journal of physiology.
[28] A. Iwama,et al. Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells. , 1993, Biochemical and biophysical research communications.
[29] E. Manseau,et al. Vascular permeability factor mRNA and protein expression in human kidney. , 1992, Kidney international.
[30] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.